<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR516.html">Part 516
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 516.145  Content and format of a request for addition to the
                            </h3>
                            <p class="depth1"><em>(a)</em> A requestor may request addition of a new animal drug to the index only after the new animal drug has been granted eligibility for indexing.</p><p class="depth1"><em>(b)</em> A requestor shall submit two copies of a dated request signed by the authorized contact for addition of a new animal drug to the index that contains the following:</p><p class="depth2"><em>(1)</em> A copy of FDA's determination of eligibility issued under Sec. 516.137;</p><p class="depth2"><em>(2)</em> A copy of FDA's written determination that the proposed qualified expert panel meets the selection criteria provided for in Sec. 516.141(b);</p><p class="depth2"><em>(3)</em> A written report that meets the requirements of Sec. 516.143;</p><p class="depth2"><em>(4)</em> A proposed index entry that contains the information described in Sec. 516.157;</p><p class="depth2"><em>(5)</em> Proposed labeling, including representative labeling proposed to be used for Type B and Type C medicated feeds if the drug is intended for use in the manufacture of medicated feeds;</p><p class="depth2"><em>(6)</em> Anticipated annual distribution of the new animal drug, in terms of the total quantity of active ingredient, after indexing;</p><p class="depth2"><em>(7)</em> A written commitment to manufacture the new animal drug and animal feeds bearing or containing such new animal drug according to current good manufacturing practices;</p><p class="depth2"><em>(8)</em> A written commitment to label, distribute, and promote the new animal drug only in accordance with the index entry;</p><p class="depth2"><em>(9)</em> The name and address of the contact person or permanent-resident U.S. agent; and</p><p class="depth2"><em>(10)</em> A draft Freedom of Information summary which includes the following information:</p><p class="depth3"><em>(i)</em> A general information section that contains the name and address of the requestor and a description of the drug, route of administration, indications, and recommended dosage.</p><p class="depth3"><em>(ii)</em> A list of the names and affiliations of the members of the qualified expert panel, not including their addresses or other contact information.</p><p class="depth3"><em>(iii)</em> A summary of the findings of the qualified expert panel concerning the target animal safety and effectiveness of the drug.</p><p class="depth3"><em>(iv)</em> Citations of all publicly-available literature considered by the qualified expert panel.</p><p class="depth3"><em>(v)</em> For an early life stage of a food-producing minor species animal, a human food safety summary.</p><p class="depth1"><em>(c)</em> Upon specific request by FDA, the requestor shall submit the information described in Sec. 516.141 that it submitted to the qualified expert panel. Any such information not in English should be accompanied by an English translation.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
